Related Experiment Video
Updated: Jul 29, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
Phenobarbital for febrile seizures--effects on intelligence and on seizure recurrence
J R Farwell1, Y J Lee, D G Hirtz
1University of Washington School of Medicine, Seattle.
Insights
Phenobarbital treatment for febrile seizures in children may lower IQ scores. These cognitive effects might persist even after discontinuing the medication, without improving seizure control.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Phenobarbital is a common treatment for pediatric febrile seizures.
- Concerns exist regarding potential behavioral and cognitive adverse effects.
Purpose of the Study:
- To evaluate the impact of phenobarbital on cognitive development in children with febrile seizures.
- To compare intelligence quotients (IQs) between children treated with phenobarbital and those receiving a placebo.
Main Methods:
- A randomized controlled trial involving 217 children aged 8–36 months with a history of febrile seizures.
- Daily phenobarbital doses (4–5 mg/kg) were administered to one group, while the other received a placebo.
- Cognitive assessments (IQs) were conducted after two years and six months post-treatment discontinuation.
Main Results:
- After two years, the phenobarbital group showed a mean IQ 7.03 points lower than the placebo group (P=0.0068).
- Six months after discontinuing phenobarbital, the mean IQ remained lower by 5.2 points (P=0.052).
- No significant difference in seizure recurrence was observed between the groups.
Conclusions:
- Phenobarbital use in treating febrile seizures is associated with a significant depression in cognitive performance.
- The observed cognitive disadvantage may persist for months after drug cessation.
- The cognitive impairment is not compensated by improved seizure prevention benefits.
Abstract:
Phenobarbital is widely used in the treatment of children with febrile seizures, although there is concern about possible behavioral and cognitive side effects. In 217 children between 8 and 36 months of age who had had at least one febrile seizure and were at heightened risk of further seizures, we compared the intelligence quotients (IQs) of a group randomly assigned to daily doses of phenobarbital (4 to 5 mg per kilogram of body weight per day) with the IQs of a group randomly assigned to placebo. After two years, the mean IQ was 7.03 [corrected] points lower in the group assigned to phenobarbital than in the placebo group (95 percent confidence interval, -11.52 to -2.5, P = 0.0068 [corrected]). Six months later, after the medication had been tapered and discontinued, the mean IQ was 5.2 points lower in the group assigned to phenobarbital (95 percent confidence interval, -10.5 to 0.04, P = 0.052). The proportion of children remaining free of subsequent seizures did not differ significantly between the treatment groups. We conclude that phenobarbital depresses cognitive performance in children treated for febrile seizures and that this disadvantage, which may outlast the administration of the drug by several months, is not offset by the benefit of seizure prevention.
Related Concept Videos
Sedatives and Hypnotics Drugs: Barbiturates
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Seizures l: Introduction

